Amgen (NQ: AMGN )
241.54 USD -0.92 (-0.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2021 Add to My Watchlist
Press releases about Amgen
Amgen Announces 2021 Third Quarter Dividend
July 30, 2021
Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will be paid on September 8, 2021, to all stockholders...
Amgen Appoints S. Omar Ishrak To Board Of Directors
July 29, 2021
Amgen (NASDAQ: AMGN) today announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of the Board's Corporate Responsibility...
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, August 3, 2021, after the close of the U.S. financial markets. The announcement will be followed...
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
July 27, 2021
Scientist´s from deCODE genetics have mapped 243 sequence variants affecting fetal growth, separating maternal genome and fetal genome. It sheds light on the relationships between hypertension,...
Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge
July 14, 2021
Challenge to Support an Innovative Solution That Addresses Disconnect in Perception of Psoriatic Disease Severity and Undertreatment Documented in Multinational UPLIFT Survey
Tezepelumab Granted Priority Review By U.S. FDA
July 08, 2021
Tezepelumab is the First and Only Biologic to Consistently and Significantly Reduce Asthma Exacerbations in a Broad Population of Patients Across Phase 2 and 3 Clinical Trials
Labcorp® (NYSE: LH), a leading global life sciences company, today announced the availability of therascreen® KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell...
Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
June 23, 2021
Migraine is a Disabling Neurological Disease that Affects More Than 8.4 Million People in Japan,
deCODE genetics: Predicting the probability of death
June 18, 2021
Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.
Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis
June 15, 2021
Campaign Aims to Empower Those Living with Plaque Psoriasis to Discover What Is Beneath the Surface of Their Condition
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and...
Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
June 04, 2021
LUMAKRAS Shows Median Overall Survival of 12.5 Months in Patients With Previously Treated Non-Small Cell Lung Cancer
Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers
June 04, 2021
Median Overall Survival was 5.7 Months Longer in Patients Treated with Bemarituzumab Compared to Chemotherapy Alone
Amgen to Webcast Investor Meeting at ASCO 2021
June 01, 2021
Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021....
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
June 01, 2021
Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready...
Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m. ET on Thursday, June 3, 2021. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen...
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
May 28, 2021
KRAS G12C, a Driver Mutation Found in About 13% of Patients With Non-Squamous Non-Small Cell Lung Cancer, is Now Actionable(1)
Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday, May 21, 2021. David M. Reese, M.D., executive vice president of Research and...
LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer
New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
May 13, 2021
NAVIGATOR Data Published in New England Journal of Medicine, and Latest Data from Tezepelumab Clinical Program Presented at ATS 2021 International Conference
Thinking about trading options or stock in Nio, Microsoft, Callaway Golf, Amgen, or Wayfair?
May 11, 2021
Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21
May 11, 2021
Final Analysis From Open-Label Extension Study in Patients with Human Immunodeficiency Virus and Dyslipidemia
deCODE genetics - Rounding off the human genome
May 10, 2021
In a study published today, scientists at deCODE Genetics demonstrate for the first time how long-read DNA sequencing can be applied at population scale to unravel large structural variants that...
Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, May 11, 2021. David M. Reese, M.D., executive vice president of...
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
May 05, 2021
Tags Featured News
Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized...